By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Cellular Dynamics International today said that its agreement with Roche to substantiate CDI's platform for assessing the potential toxicity of drug candidates for heart disease has progressed to a standard supply agreement.

The two-year agreement, which took effect in March 2009, to substantiate CDI's iCell Cardiomyocytes as a predictive tool was completed early, and the platform will now be incorporated into Roche's drug development decision-making process, CDI said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.